Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 5;122(10):1746-9.
doi: 10.1182/blood-2013-03-492678. Epub 2013 Jul 17.

Implications of continued response after autologous stem cell transplantation for multiple myeloma

Wilson I Gonsalves  1 , Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Yi Lin, Preet P Singh, Vinay Gupta, Suzanne R Hayman, Francis K Buadi, David Dingli, Prashant Kapoor, Arleigh R McCurdy, Shaji K Kumar
Affiliations

Implications of continued response after autologous stem cell transplantation for multiple myeloma

Wilson I Gonsalves et al. Blood. .

Abstract

Patients undergoing autologous stem cell transplantation (ASCT) for multiple myeloma (MM) undergo disease assessment approximately 100 days later. Some patients continue to have a decline in their serum or urine monoclonal protein after day 100 in the absence of additional therapy. We evaluated 430 MM patients who underwent ASCT within 12 months of their diagnosis and had not achieved a complete remission at day 100. Of these patients, 167 (39%) had a continued response after day 100 without additional therapy. When compared with patients who did not (n = 263), those who had a continued response had a longer progression-free survival (35 vs 13 months, P < .001), time to next therapy (43 vs 16 months, P < .001), and overall survival (96 vs 57 months, P < .001). This phenomenon of a continued response maintained prognostic value in a multivariable analysis and should be considered when interpreting posttransplant responses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impact of continued response after ASCT on survival outcomes. Shows the Kaplan-Meier curve (A) for PFS, (B) TTNT, and (C) OS after ASCT in patients not achieving a CR at day 100 based on the presence of a continued response or no further response.
See this image and copyright information in PMC

References

    1. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115–1123. - PubMed
    1. Kumar S. Stem cell transplantation for multiple myeloma. Curr Opin Oncol. 2009;21(2):162–170. - PMC - PubMed
    1. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473. - PubMed
    1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9. - PMC - PubMed
    1. Kapoor P, Fonseca R, Rajkumar SV, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clinic Proc. 2010;85(6):532–537. - PMC - PubMed

Publication types